Next Article in Journal
Rett Syndrome: Treatment with IGF-I, Melatonin, Blackcurrant Extracts, and Rehabilitation
Previous Article in Journal
TB Presenting as Recurrent Pneumonia in a HIV-Infected Infant in Central Viet Nam
Article Menu

Export Article

Open AccessCase Report
Reports 2018, 1(2), 13; https://doi.org/10.3390/reports1020013

Successful Amplified-Natural-Killer Cell (ANK) Therapy Administered to a Patient with Smoldering Adult T-Cell Leukemia in Acute Crisis

1
Higashinotoin Clinic, 338 Enfukuji, Nakagyo, Kyoto 604-8175, Japan
2
Ebino Centro Clinic, 1007-4, Ooazauwae, Ebino, Miyazaki 889-4384, Japan
3
Department of Health Science and Social Welfare, Kibi International University, 8 Igamachi, Takahashi 716-8508, Japan
*
Author to whom correspondence should be addressed.
Received: 22 July 2018 / Revised: 7 August 2018 / Accepted: 13 August 2018 / Published: 14 August 2018
Full-Text   |   PDF [1669 KB, uploaded 14 August 2018]   |  

Abstract

Adult T-cell leukemia (ATL) is an indolent leukemia caused by type 1 human T-cell leukemia virus (HTLV-1). A variety of therapeutic interventions via immunological approaches have been attempted. ATL cells express costimulatory molecules of natural killer (NK) cells, and a new modality—amplified NK (ANK) cell treatment—was administered here to a patient with ATL. A 70-year-old female presenting with ringworm infection received a diagnosis of smoldering ATL in 2004. Monitoring of soluble IL-2 receptors (sIL-2Rs) in the serum showed disease exacerbation in 2007, associated with the enlargement of lymph nodes and formation of a skin tumor. NK cells were amplified by in vitro cell culture methods. To avoid cytokine release syndrome, 2–5 × 108 cells were administered with each injection. A total of 15 injections from 12 November 2007 to 15 February 2008 were administered to this patient. This case showed drastic downregulation of sIL-2R, resulting in the induction of complete remission, which lasted for >5 years. This is the first report of treatment of a patient with ATL using ANK cell therapy. More attempts of this therapy will enhance our insight into the appropriate application of this new therapy to clinically diverse patients. View Full-Text
Keywords: ATL; CD3; T cell receptor; HTLV-1; NK cells; therapy ATL; CD3; T cell receptor; HTLV-1; NK cells; therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Teshigawara, K.; Nagai, S.; Bai, G.; Okubo, Y.; Chagan-Yasutan, H.; Hattori, T. Successful Amplified-Natural-Killer Cell (ANK) Therapy Administered to a Patient with Smoldering Adult T-Cell Leukemia in Acute Crisis. Reports 2018, 1, 13.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Reports EISSN 2571-841X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top